Pfizer
Pfizer Advances Development of Once-Daily Oral GLP-1 Receptor Agonist Danuglipron for Obesity Treatment
Pfizer, Danuglipron, GLP-1 Receptor Agonist, Obesity Treatment, Once-Daily Formulation, Clinical Trials, Weight Loss Medication
Pfizer Faces Key R&D Challenges as Chief Scientific Officer Mikael Dolsten Departs
Pfizer, Mikael Dolsten, Chief Scientific Officer, R&D Challenges, Biopharma Industry
Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership
Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply
Pfizer’s Continuous Cost-Cutting: A $4B Savings Drive Extended to 2027
Pfizer, cost-cutting, savings drive, 2027, pharmaceutical industry, restructuring, efficiency, profitability.
Sen. Wyden Scrutinizes Pfizer’s Tax Rate Amidst Ongoing Investigation
Sen. Wyden, Pfizer, tax rate, investigation, corporate taxation, tax avoidance, pharmaceutical industry, financial transparency
AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case
AstraZeneca, Pfizer, Tagrisso, patent infringement, jury verdict, damages, lung cancer treatment
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.